Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 4,086 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Recruiting Phase 2 Interventional

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

NCT05645718
View directory record Official record
Conditions
Leukemia
Interventions
Cyclophosphamide, Vincristine, Blinatumomab, Methotrexate, Cytarabine, Mercaptopurine, Prednisone, Pegfilgrastim, Inotuzumab ozogamicin, Rituximab, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 25 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 3 Interventional

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

NCT00649025
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
21
States / cities
Scottsdale, Arizona • Tempe, Arizona • Encinitas, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD

NCT03103750
View directory record Official record
Conditions
ADHD
Interventions
Magnetic Resonance Imaging (MRI), PHNO, calcitriol, Placebo oral capsule, high-resolution research tomography, Dextro Amphetamine
Procedure · Drug · Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 17, 2026, 10:37 AM EDT
Active, not recruiting Phase 1 Interventional

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

NCT04731376
View directory record Official record
Conditions
Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder, Urinary System Neoplasm
Interventions
Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate
Other · Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 17, 2026, 10:37 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

NCT00074490
View directory record Official record
Conditions
Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
Interventions
Rituximab, Fludarabine, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Peripheral blood stem cell (PBSC) transplantation, T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells, Prednisone, Allogeneic hematopoietic stem cell transplant (HSCT), Filgrastim, T-Rapa cell Donor Lymphocyte Infusion (DLI)
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Years to 90 Years
Enrollment
442 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 17, 2026, 10:37 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01145508
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Docetaxel, Laboratory Biomarker Analysis, Prednisone, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Rilimogene Galvacirepvec
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
14
States / cities
Jacksonville, Florida • Chicago, Illinois • Highland Park, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 17, 2026, 10:37 AM EDT
Completed No phase listed Observational

Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia

NCT00085176
View directory record Official record
Conditions
Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Years to 16 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 17, 2026, 10:37 AM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis

NCT00890968
View directory record Official record
Conditions
Hand Dermatoses
Interventions
Triamcinolone Acetonide (TAC) DuraPeel, Placebo DuraPeel
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
San Diego, California • Clinton Township, Michigan • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 1 Interventional

ZD6474 to Treat Advanced Brain Cancer in Patients

NCT00272350
View directory record Official record
Conditions
Recurrent High-Grade Gliomas, Progressive Low-Grade Gliomas, Malignant Gliomas
Interventions
Steroids, ZD6474
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Oct 17, 2026, 10:37 AM EDT
Withdrawn Phase 2 Interventional

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

NCT01539174
View directory record Official record
Conditions
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 17, 2026, 10:37 AM EDT
Recruiting Phase 4 Interventional

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

NCT05282277
View directory record Official record
Conditions
Depression, Psychosis, Anhedonia
Interventions
Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

ER Reactivation Therapy for Breast Cancer

NCT02188745
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
17B-estradiol, Letrozole, Anastrozole, Exemestane
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Methotrexate and Mycophenolate Mofetil for UVEITIS

NCT01829295
View directory record Official record
Conditions
Uveitis
Interventions
Mycophenolate mofetil, Methotrexate, Prednisone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

NCT02652130
View directory record Official record
Conditions
Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease
Interventions
Remestemcel-L
Biological
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 17, 2026, 10:37 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Coagulation and Fibrinolysis of Estradiol in Transwomen

NCT05387577
View directory record Official record
Conditions
Transgenderism, Clotting Disorder
Interventions
Estradiol Tablets, Transdermal patch
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 17, 2026, 10:37 AM EDT
Terminated Phase 4 Interventional Results available

Steroids in Total Knee Arthroplasty

NCT02219581
View directory record Official record
Conditions
Postoperative Pain, Inflammation, Osteoarthritis
Interventions
Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo
Drug
Lead sponsor
Thomas L Bradbury
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 17, 2026, 10:37 AM EDT
Recruiting Phase 2 Interventional

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

NCT04776395
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer

NCT00976339
View directory record Official record
Conditions
Breast Cancer
Interventions
Cholecalciferol
Drug
Lead sponsor
Katherine D. Crew
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 17, 2026, 10:37 AM EDT
Terminated Not applicable Interventional Results available

Repeat Emergency Department Visits Among Patients With Asthma and COPD

NCT02499887
View directory record Official record
Conditions
Asthma, COPD
Interventions
beclamethasone dipropionate, albuterol, Prednisone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 17, 2026, 10:37 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

NCT03984448
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
634
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sterile Amniotic Fluid Filtrate Epidural Injection.

NCT04537026
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Amniotic Fluid Allograft, Dexamethasone sodium phosphate
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 10:37 AM EDT
Completed Early Phase 1 Interventional

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

NCT01760226
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 17, 2026, 10:37 AM EDT